Leukemia in a patient treated with growth hormone

Endocr J. 2000 Aug;47(4):471-3. doi: 10.1507/endocrj.47.471.


It is well known that growth hormone (GH) therapy is associated with increased risk of development of malignant tumors, especially leukemia. In the case presented, growth hormone treatment was initiated in a 25-year-old patient with hypopituitarism. After 4 months of therapy with thrice a week injections of rhGH, acute myelogenous leukemia developed. It was thought that no clearcut evidence existed to establish a relationship between the growth hormone treatment and development of acute leukemia.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Growth Hormone / adverse effects*
  • Growth Hormone / therapeutic use*
  • Humans
  • Hypopituitarism / drug therapy
  • Leukemia, Myeloid, Acute / chemically induced*
  • Leukemia, Myeloid, Acute / epidemiology
  • Male
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Risk Factors


  • Recombinant Proteins
  • Growth Hormone